Provided by Tiger Trade Technology Pte. Ltd.

ArTara Therapeutics, Inc.

3.55
-0.1500-4.05%
Post-market: 3.620.0700+1.97%19:30 EDT
Volume:3.95M
Turnover:14.11M
Market Cap:209.79M
PE:-2.62
High:3.73
Open:3.69
Low:3.45
Close:3.70
52wk High:7.82
52wk Low:3.11
Shares:59.10M
Float Shares:57.41M
Volume Ratio:4.04
T/O Rate:6.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3535
EPS(LYR):-1.3409
ROE:-45.80%
ROA:-28.82%
PB:1.30
PE(LYR):-2.65

Loading ...

JonesTrading Remains a Buy on Protara Therapeutics (TARA)

TIPRANKS
·
Apr 07

Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results

TIPRANKS
·
Mar 30

Protara warrants set to expire June 29 after trial endpoint met

Reuters
·
Mar 30

Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway

TIPRANKS
·
Mar 20

Protara Therapeutics (TARA) Receives a Buy from Oppenheimer

TIPRANKS
·
Mar 11

Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028

TIPRANKS
·
Mar 11

Protara Q4 net loss widens on higher R&D spend

Reuters
·
Mar 10

BRIEF-Protara Therapeutics Q4 EPS USD -0.37

Reuters
·
Mar 10

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

THOMSON REUTERS
·
Mar 10

Protara Therapeutics Q4 Operating Expenses USD 19.079 Million

THOMSON REUTERS
·
Mar 10

Protara Therapeutics Q4 Net Income USD -17.307 Million

THOMSON REUTERS
·
Mar 10

Protara Therapeutics Inc - on Track to Initiate Advanced-3 Registrational Trial in Bcg-NaÏVe Patients in 2H 2026

THOMSON REUTERS
·
Mar 10

Protara Therapeutics Q4 Income From Operations USD -19.079 Million

THOMSON REUTERS
·
Mar 10

Protara Therapeutics Inc - Expects to Complete Enrollment of Bcg-Unresponsive Cohort of Advanced-2 Trial in 2H 2026

THOMSON REUTERS
·
Mar 10

Protara Therapeutics Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
Feb 27

BUZZ-U.S. STOCKS ON THE MOVE-Henry Schein, Domino's Pizza, FactSet

Reuters
·
Feb 24

BUZZ-Protara tumbles as cancer drug data falls short of investor expectations

Reuters
·
Feb 24

Buy Rating on TARA-002 Supported by Comparable Efficacy and $500M Peak Sales Opportunity in Bladder Cancer

TIPRANKS
·
Feb 24

Protara Therapeutics says TARA-002 demonstrates 68% CR rate at 6 months

TIPRANKS
·
Feb 24

Protara reports 68% six-month complete response with TARA-002 in BCG-unresponsive bladder cancer trial

Reuters
·
Feb 24